AtaiBeckley (ATAI) Cash from Operations (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Cash from Operations came in at 21090000.0 in Q1 2026, down 18.21% year-on-year from 25785820.31 in Q1 2025, and down 18.21% quarter-over-quarter from 17841000.0 in Q1 2025.
AtaiBeckley (ATAI) Cash from Operations (2020 - 2026) Analysis & Trends
AtaiBeckley's Cash from Operations history runs 2 years deep, the most recent figure standing at 21090000.0 for Q1 2026.
- For the quarter ending Q3 2025, Cash from Operations fell 20.27% year-over-year to 23261000.0; the trailing twelve-month figure through Sep 2025 stood at 79491000.0 (up 0.77% YoY), and the FY2024 full-year result was 82437000.0, up 2.0% from the prior year.
- Cash from Operations retreated to 23261000.0 in Q3 2025, from 14094000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 100000.0 in Q1 2021 to a low of 30505000.0 in Q4 2022.
- A 5-year average of 20498105.26 and a median of 21931000.0 in 2022 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations tumbled 24086.0% in 2022 and soared 34.28% in 2023, its largest moves.
- Tracing ATAI's Cash from Operations over 5 years: stood at 20509000.0 in 2021, then tumbled by 48.74% to 30505000.0 in 2022, then increased by 28.01% to 21962000.0 in 2023, then decreased by 10.62% to 24295000.0 in 2024, then climbed by 4.26% to 23261000.0 in 2025.
- Business Quant data shows ATAI's Cash from Operations at 23261000.0 in Q3 2025, 14094000.0 in Q2 2025, and 17841000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - | -23.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.09 Mn |
| Mar 31, 2026 | -21.09 Mn |
| Sep 30, 2025 | -23.26 Mn |
| Sep 30, 2025 | -23.26 Mn |
| Jun 30, 2025 | -14.09 Mn |
| Jun 30, 2025 | -14.09 Mn |
| Mar 31, 2025 | -17.84 Mn |
| Mar 31, 2025 | -17.84 Mn |
| Mar 31, 2025 | -17.84 Mn |
| Mar 31, 2025 | -17.84 Mn |
| Dec 31, 2024 | -24.30 Mn |
| Dec 31, 2024 | -24.30 Mn |
| Sep 30, 2024 | -19.34 Mn |
| Sep 30, 2024 | -19.34 Mn |
| Jun 30, 2024 | -16.23 Mn |
| Jun 30, 2024 | -16.23 Mn |
| Mar 31, 2024 | -22.57 Mn |
| Mar 31, 2024 | -22.57 Mn |
| Dec 31, 2023 | -21.96 Mn |
| Dec 31, 2023 | -21.96 Mn |